Effectiveness and safety of iGlarLixi (insulin glargine 100 U/mL plus lixisenatide) in type 2 diabetes according to the timing of daily administration : data from the REALI pooled analysis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00083841" target="_blank" >RIV/00023001:_____/23:00083841 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/23:10458847
Result on the web
<a href="https://link.springer.com/article/10.1007/s13300-023-01375-8" target="_blank" >https://link.springer.com/article/10.1007/s13300-023-01375-8</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s13300-023-01375-8" target="_blank" >10.1007/s13300-023-01375-8</a>
Alternative languages
Result language
angličtina
Original language name
Effectiveness and safety of iGlarLixi (insulin glargine 100 U/mL plus lixisenatide) in type 2 diabetes according to the timing of daily administration : data from the REALI pooled analysis
Original language description
IntroductioniGlarLixi (insulin glargine 100 U/mL plus lixisenatide) has demonstrated glycaemic efficacy and safety in adults with inadequately controlled type 2 diabetes mellitus (T2DM). Per the European Medicines Agency's product label, iGlarLixi should be injected once a day within 1 h prior to a meal, preferably the same meal every day when the most convenient meal has been chosen. It is however unknown whether iGlarLixi administration timing affects glycaemic control and safety, as clinical trial evidence is mainly based on pre-breakfast iGlarLixi administration. Therefore, we assessed the effectiveness and safety of iGlarLixi in clinical practice, according to its administration timing.MethodsData were pooled from two prospective observational studies including 1303 European participants with T2DM inadequately controlled on oral antidiabetic drugs with or without basal insulin who initiated iGlarLixi therapy for 24 weeks. Participants were classified into four subgroups based on daily timing of iGlarLixi injection: pre-breakfast (N = 436), pre-lunch (N = 262), pre-dinner (N = 399), and those who switched iGlarLixi injection time during the study (N = 206).ResultsNo meaningful differences in baseline characteristics were observed between the study groups. Least-squares mean reductions in haemoglobin A1c (HbA1c) from baseline to week 24 were substantial in all groups, with the numerically largest decrease observed in the pre-breakfast group (1.57%) compared with the pre-lunch (1.27%), pre-dinner (1.42%), or changed injection time (1.33%) groups. Pre-breakfast iGlarLixi injection also resulted in a numerically greater proportion of participants achieving HbA1c < 7.0% at week 24 (33.7% versus 19.0% for pre-lunch, 25.6% pre-dinner, and 23.2% changed injection time). iGlarLixi was well tolerated across all groups, with low rates of gastrointestinal disorders and hypoglycaemia. Mean body weight decreased similarly in all groups (by 1.3-2.3 kg).ConclusioniGlarLixi was effective and safe regardless of its daily administration time. However, pre-breakfast iGlarLixi injection resulted in a more effective glycaemic control.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30202 - Endocrinology and metabolism (including diabetes, hormones)
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Diabetes therapy
ISSN
1869-6953
e-ISSN
1869-6961
Volume of the periodical
14
Issue of the periodical within the volume
4
Country of publishing house
DE - GERMANY
Number of pages
14
Pages from-to
639-652
UT code for WoS article
000931738900001
EID of the result in the Scopus database
2-s2.0-85148010415